Overview

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

Status:
Completed

Trial end date:
2019-06-28

Target enrollment:

Participant gender:

Summary

Compare the incidence of severe clinical exacerbations in the treatment of ABPA, between a strategy with a maintenance treatment and a conventional strategy without antifungal maintenance therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Poitiers University Hospital

Treatments:

Amphotericin B
Liposomal amphotericin B